Work at Artivila (Shenzhen) Innovation Center Ltd. has led to the discovery of new leucine-rich repeat kinase 2 (LRRK2; Dardarin) inhibitors reported to be useful for the treatment of cancer, leprosy, tuberculosis, colitis, inflammatory bowel disease, Alzheimer’s, Parkinson’s and Huntington’s disease.
New protein arginine N-methyltransferase 5 (PRMT5) inhibitors are detailed in a Scinnohub Pharmaceutical Co. Ltd. patent and described as potentially useful for the treatment of cancer.
A recent patent from Korea University Research & Business Foundation Sejong Campus describes quinazoline-benzimidazole derivatives acting as microtubule destabilizers (tubulin polymerization inhibitors) and HER2 inhibitors reported to be useful for the treatment of cancer.
Researchers from First Affiliated Hospital of Zhengzhou University published results from a study that aimed to investigate the mechanisms by which programmed cell death and mitochondrial function influence prognosis and immunotherapy response in renal cell carcinoma (RCC), and to identify novel therapeutic targets for this disease.
Everest Medicines Ltd. has obtained IND clearance from the FDA for EVM-14, an off-the-shelf mRNA cancer vaccine targeting multiple tumor-associated antigens and designed to treat various cancers, including non-small-cell lung cancer and head and neck cancer.
Esophageal squamous cell carcinoma (ESCC) accounts for about 90% of esophageal cancer cases and is the sixth most common cause of cancer death worldwide. Targeting cancer stem cells offers a therapeutic approach for addressing cancer, concretely in those cases that are resistant to cisplatin.
Scientists at the Institute of Cancer Research (ICR) in the U.K. are developing a technology that analyzes, in vitro, how the 3D morphology of cancer cells changes when exposed to a compound, using AI to predict their response to new treatments. The researchers estimate that their methodology could accelerate drug development by 6 years, by ruling out unsuccessful drugs and thus reducing the number of preclinical trials.
Eikon Therapeutics Inc. has identified Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.
RSS
